Wells Fargo & Company Neu Base Therapeutics, Inc. Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.17 - $0.39 $678 - $1,556	-3,992 Reduced 76.34%	1,237 $0
Q4 2022 Feb 13, 2023	BUY	$0.18 - $0.3 $721 - $1,201	4,006 Added 327.56%	5,229 $0
Q3 2022 Nov 14, 2022	BUY	$0.41 - $1.3 $418 - $1,326	1,020 Added 502.46%	1,223 $0
Q2 2022 Aug 12, 2022	BUY	$0.82 - $1.93 $10 - $25	13 Added 6.84%	203 $0
Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $13 - $19	-4 Reduced 2.06%	190 $1,000
Q2 2021 Aug 16, 2021	SELL	$4.63 - $7.34 $28,150 - $44,627	-6,080 Reduced 96.91%	194 $1,000
Q1 2021 May 13, 2021	SELL	$6.92 - $12.36 $183,746 - $328,195	-26,553 Reduced 80.89%	6,274 $46,000
Q4 2020 Feb 09, 2021	BUY	$6.92 - $9.25 $18,497 - $24,725	2,673 Added 8.86%	32,827 $230,000
Q3 2020 Nov 05, 2020	BUY	$7.25 - $9.71 $37,127 - $49,724	5,121 Added 20.46%	30,154 $229,000
Q2 2020 Aug 13, 2020	BUY	$6.69 - $11.51 $163,182 - $280,751	24,392 Added 3805.3%	25,033 $220,000
Q1 2020 May 14, 2020	BUY	$4.77 - $8.23 $3,057 - $5,275	641 New	641 $4,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.